Cogent Biosciences (COGT) Total Liabilities (2017 - 2026)

Cogent Biosciences' Total Liabilities history runs 10 years deep, the most recent figure standing at $295.3 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 355.71% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.71% YoY), while the FY2025 annual figure was $301.2 million, up 320.65% from the prior year.
• Total Liabilities was $295.3 million for Q1 2026 at Cogent Biosciences, down from $301.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $301.2 million in Q4 2025 to a low of $19.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $88.2 million across 5 years, with a median of $55.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities slipped 5.84% in 2023, then soared 355.71% in 2026.
• A 5-year view of Total Liabilities shows it stood at $45.1 million in 2022, then grew by 23.43% to $55.6 million in 2023, then grew by 28.72% to $71.6 million in 2024, then soared by 320.65% to $301.2 million in 2025, then slipped by 1.97% to $295.3 million in 2026.
• The last three Total Liabilities figures came in at $295.3 million (Q1 2026), $301.2 million (Q4 2025), and $123.5 million (Q3 2025), per Business Quant data.